SEC Form 4 · accession 0001209191-18-029966
Insys Therapeutics, Inc. · INSY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Brian Tambi
Director
Period of report
Feb 21, 2018
Accepted (ET)
May 14, 2018 · 5:50 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001516479
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 21, 2018 | A | 4,000 | $0.00 | A | 4,000 | D | |
| Common Stock | May 10, 2018 | M | 33,654 | $0.61 | A | 37,654 | D | |
| Common Stock | May 10, 2018 | M | 68,850 | $1.62 | A | 106,504 | D | |
| Common Stock | May 10, 2018 | M | 60,000 | $3.63 | A | 166,504 | D | |
| Common StockF1 | May 10, 2018 | S | 166,504 | $6.41 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF2,F3 | — | Feb 21, 2018 | D | 4,000 | D | — | — | Common Stock | 4,000 | 0 | D |
| Stock Option (right to buy)F4,F5 | $0.61 | May 10, 2018 | M | 33,654 | D | — | Feb 21, 2020 | Common Stock | 33,654 | 0 | D |
| Stock Option (right to buy)F4,F5 | $1.62 | May 10, 2018 | M | 68,850 | D | — | Mar 28, 2021 | Common Stock | 68,850 | 0 | D |
| Stock Option (right to buy)F4,F5 | $3.63 | May 10, 2018 | M | 60,000 | D | — | May 13, 2023 | Common Stock | 60,000 | 0 | D |
Explanation of responses
- F1The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.28 to $6.61 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F2Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- F3The restricted stock units ("RSUs") vested on the one year anniversary of the date of grant.
- F4The exercise price reflects a 3-for-2 forward stock split effected by the Issuer on March 28, 2014 and a 2-for-1 forward stock split effected by the Issuer on June 5, 2015.
- F5The option is fully vested and exercisable.